The effect of EDI3 on tumor growth and metastasis is being studied using orthotopic and experimental models of breast and ovarian cancer. Histological analysis as well as transcriptomics, and metabolomics profiling of the primary tumors will be done, comparing tumors with high and low EDI3 expression, in addition to primary tumor versus metastases. The hypothesis is that tumors with high levels of EDI3 cause deregulation of metabolic pathways that lead to altered cellular function.
